Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19686530 | 0.90 | ADORA2A (0.32) | ADORA2AADORA1ALOX15 | |
| SCHEMBL21144176 | 0.80 | HTT (0.45) | ADORA2AADORA1CYP3A4ALDH1A1LMNA | |
| SCHEMBL21143702 | 0.79 | ADORA2A (0.33) | ADORA2AADORA1CYP3A4ALDH1A1LMNA | |
| SCHEMBL21144222 | 0.79 | ADORA2A (0.33) | ADORA2AADORA1CYP3A4ALDH1A1LMNA | |
| SCHEMBL21143687 | 0.79 | ADORA2A (0.35) | ADORA2AADORA1CYP3A4ALDH1A1LMNA | |
| SCHEMBL19686528 | 0.78 | KCNN2 (0.48) | ADORA2AADORA1CYP3A4ALOX15 | |
| SCHEMBL21144303 | 0.78 | ADORA2A (0.43) | ADORA2AADORA1CYP3A4 | |
| SCHEMBL19687474 | 0.69 | ADORA2A (0.32) | ADORA2AADORA1ALOX15 | |
| SCHEMBL19686529 | 0.69 | ADORA2A (0.31) | ADORA2AADORA1ALOX15 | |
| SCHEMBL19686527 | 0.69 | ADORA2A (0.32) | ADORA2AADORA1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | ADORA2A 1711/4885ADORA1 1011/4885CYP3A4 1136/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | ADORA2A 1711/4885ADORA1 1011/4885CYP3A4 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.